Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether COX-2 inhibitor is effective in the treatment of primary hypertrophic osteoarthropathy
Patients with primary hypertrophic osteoarthropathy(PHO) were diagnosed based on clinical manifestations and symptoms. PHO patients were treated with COX-2 inhibitor after signing informed consent. The extend of alleviation, the change of the markers on prostaglandin E metabolic pathway and the adverse event on different time points were recorded to identify the efficacy and safety.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COX-2 Inhibitor | Experimental | Patients who take COX-2 inhibitor |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| COX-2 inhibitor | Drug | oral COX-2 inhibitor intake 60mg qd |
|
| Measure | Description | Time Frame |
|---|---|---|
| Prostaglandin E2（PGE2） level change after COX-2 inhibitor treatment in PHO patients | measure the serum prostaglandin E2 level at 3 months | 3 months |
| Prostaglandin E2（PGE2） level change after COX-2 inhibitor treatment in PHO | measure the serum prostaglandin E2 level at 6 months | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| change in pain on VAS scale after COX-2 inhibitor treatment | use Visual Analogue Score (VAS) to evaluate pain | 3 months |
| change in pain on VAS scale after COX-2 inhibitor treatment | 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Weibo Xia, MD | Contact | 86-10-6915-5076 | xiaweibo@medmail.com.cn |
| Name | Affiliation | Role |
|---|---|---|
| Weibo Xia, MD | Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking Union Medical College Hospital | Recruiting | Beijing | Beijing Municipality | 100005 | China |
Not provided
| ID | Term |
|---|---|
| D010004 | Osteoarthropathy, Primary Hypertrophic |
| ID | Term |
|---|---|
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D007592 | Joint Diseases |
| D030342 | Genetic Diseases, Inborn |
Not provided
Not provided
| ID | Term |
|---|---|
| D052246 | Cyclooxygenase 2 Inhibitors |
| D000077613 | Etoricoxib |
| ID | Term |
|---|---|
| D016861 | Cyclooxygenase Inhibitors |
| D004791 | Enzyme Inhibitors |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| change in pain on VAS scale after COX-2 inhibitor treatment | 12 months |
| The volume of distal part of middle finger change after COX-2 inhibitor treatment | Both left and right fingers were measured twice and the average value was defined as volume of distal part of middle finger | 3 months |
| The volume of distal part of middle finger change after COX-2 inhibitor treatment | Both left and right fingers were measured twice and the average value was defined as volume of distal part of middle finger | 6 months |
| The volume of distal part of middle finger change after COX-2 inhibitor treatment | Both left and right fingers were measured twice and the average value was defined as volume of distal part of middle finger | 12 months |
| Circumference of knee joint change after COX-2 inhibitor treatment | During the circumference of knee joint (CKJ) assessment, the patient was standing straight and the knee was extended as much as possible. The tester stood closest to the examined leg and used a tape to measure the circumference just at the base of the patella. Both legs were measured twice and the average value was used as CKJ. | 3 months |
| Circumference of knee joint change after COX-2 inhibitor treatment | During the circumference of knee joint (CKJ) assessment, the patient was standing straight and the knee was extended as much as possible. The tester stood closest to the examined leg and used a tape to measure the circumference just at the base of the patella. Both legs were measured twice and the average value was used as CKJ. | 6 months |
| Circumference of knee joint change after COX-2 inhibitor treatment | During the circumference of knee joint (CKJ) assessment, the patient was standing straight and the knee was extended as much as possible. The tester stood closest to the examined leg and used a tape to measure the circumference just at the base of the patella. Both legs were measured twice and the average value was used as CKJ. | 12 months |
| D009358 |
| Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D020164 | Chemical Actions and Uses |
| D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| D018712 | Analgesics, Non-Narcotic |
| D000700 | Analgesics |
| D018689 | Sensory System Agents |
| D018373 | Peripheral Nervous System Agents |
| D045505 | Physiological Effects of Drugs |
| D000893 | Anti-Inflammatory Agents |
| D045506 | Therapeutic Uses |
| D018501 | Antirheumatic Agents |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |